Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

The information provided on this website about Caboxen and cabozantinib is intended for general educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, treatment recommendations, or consultation with a qualified healthcare professional.

Cabozantinib is a prescription anticancer medicine that can cause serious and potentially life-threatening adverse reactions. Its use requires appropriate medical assessment, specialist supervision, and regular monitoring.

Patients should always consult their oncologist or another qualified healthcare professional before starting, changing, interrupting, or stopping cabozantinib treatment.

1. General Medical Information

The content on this website is intended to help readers understand cabozantinib, including its mechanism of action, potential uses, dosage considerations, precautions, and possible adverse reactions.

Medical information may change as new clinical evidence, safety findings, and regulatory decisions become available.

Although reasonable care should be taken when preparing medical content, no guarantee is made that every statement is complete, current, or applicable to every patient or product.

Individual treatment decisions must be based on professional medical assessment and the prescribing information applicable to the specific medicine.

2. No Substitute for Professional Medical Advice

Information on this website should not be interpreted as an individual medical recommendation.

It does not replace:

  • Consultation with an oncologist.
  • Assessment by a qualified physician.
  • Review of medical history.
  • Interpretation of laboratory results.
  • Evaluation of cancer stage and progression.
  • Professional review of other medicines.
  • Individualized treatment planning.
  • Emergency medical care.

Patients should not make treatment decisions based solely on information presented on this website.

3. Prescription Medicine Disclaimer

Cabozantinib is a prescription anticancer medicine.

It should only be used when prescribed by a qualified healthcare professional for an appropriate medical indication.

Patients should not:

  • Start treatment without a valid prescription.
  • Use another person’s medicine.
  • Change the prescribed dose independently.
  • Combine different cabozantinib formulations without professional guidance.
  • Stop treatment without consulting their oncologist.
  • Share their medicine with another person.

The prescribing specialist must determine whether cabozantinib is appropriate for the patient’s condition.

4. Product Identity and Manufacturer Information

Caboxen is identified on this website as a cabozantinib product presented in 20 mg and 80 mg strengths.

However, the exact manufacturer, product-specific regulatory authorization, and dosage form must be confirmed through reliable product documentation.

The information presented on this website should not be interpreted as independent confirmation of:

  • Product authenticity.
  • Manufacturer identity.
  • Manufacturing standards.
  • Regulatory approval.
  • Product registration.
  • Pharmaceutical equivalence.
  • Availability in a particular country.

Patients and healthcare professionals should verify these details before using the product.

5. Dosage and Administration Disclaimer

Cabozantinib dosing depends on the approved indication, formulation, treatment regimen, and individual patient factors.

The information on this website must not be used to determine or modify an individual’s dose.

Cabozantinib tablets and capsules have different pharmaceutical characteristics and administration instructions. They are not bioequivalent and should not be substituted for one another.

Patients must follow the prescribing instructions for their exact product and should ask their healthcare professional if any administration detail is unclear.

6. Side Effects and Safety Disclaimer

Cabozantinib can cause common and serious adverse reactions.

Potential safety concerns include:

  • High blood pressure.
  • Diarrhea.
  • Fatigue.
  • Nausea and vomiting.
  • Decreased appetite.
  • Weight loss.
  • Hand-foot skin reactions.
  • Liver-related abnormalities.
  • Severe bleeding.
  • Blood clots.
  • Gastrointestinal perforation.
  • Fistula formation.
  • Impaired wound healing.
  • Proteinuria.
  • Osteonecrosis of the jaw.
  • Harm to an unborn baby.

This list is not exhaustive. Other adverse reactions may occur.

Patients should report new, persistent, or worsening symptoms to their healthcare professional.

Severe bleeding, chest pain, sudden difficulty breathing, severe abdominal pain, or sudden neurological symptoms require urgent medical evaluation.

7. Drug Interactions Disclaimer

Cabozantinib may interact with other prescription medicines, nonprescription medicines, supplements, and herbal products.

Certain medicines that affect the CYP3A4 enzyme may alter cabozantinib exposure.

Patients should inform their healthcare professional about everything they take, including:

  • Prescription medicines.
  • Over-the-counter medicines.
  • Vitamins.
  • Herbal preparations.
  • Dietary supplements.
  • Other anticancer treatments.

Patients should not start or stop another medicine without discussing potential interactions with their healthcare professional.

8. Pregnancy and Breastfeeding Disclaimer

Cabozantinib may cause harm to an unborn baby.

Women who are pregnant, planning pregnancy, or who could become pregnant should discuss the risks and appropriate contraception requirements with their healthcare professional before treatment.

Breastfeeding should also be discussed with the prescribing specialist because cabozantinib may pose risks to a nursing infant.

Patients should follow the pregnancy prevention and breastfeeding instructions provided in the applicable prescribing information.

9. Individual Treatment Response

Not every patient responds to cabozantinib in the same way.

Treatment outcomes may depend on:

  • Cancer type and stage.
  • Tumor characteristics.
  • Previous treatment.
  • Overall health.
  • Kidney and liver function.
  • Prescribed formulation and dose.
  • Treatment tolerance.
  • Other medical conditions.

Information about possible treatment benefits should not be interpreted as a guarantee of effectiveness or a promise of a particular outcome.

Only the treating oncology team can assess an individual’s response to therapy.

10. External Medical and Regulatory Information

Medicine approvals, prescribing recommendations, and availability may differ between countries.

The approved indications for cabozantinib tablets are not necessarily the same as those for cabozantinib capsules.

Patients and healthcare professionals should consult the applicable national regulatory authority and official prescribing information for the specific product.

11. Limitation of Responsibility

To the extent permitted by applicable law, the website and its content providers are not responsible for medical decisions made solely on the basis of information presented here.

Readers remain responsible for seeking appropriate professional medical advice before making treatment decisions.

Nothing on this website establishes a doctor-patient relationship or guarantees a particular medical outcome.

12. Updates to This Disclaimer

Medical knowledge, prescribing recommendations, and regulatory requirements may change over time.

This disclaimer and the accompanying website content may be revised when necessary to reflect updated information.

Readers should review the relevant product documentation and consult qualified healthcare professionals for current medical guidance.

Final Medical Notice

Caboxen is identified as a cabozantinib product in 20 mg and 80 mg strengths. Its exact dosage form, manufacturer, and product-specific regulatory status should be confirmed before use.